Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU C

[News]

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

More... (http://www.news-medical.net/news/20100428/Phase-I-clinical-trial-results-of-AE37-in-prostate-cancer-patients-presented-at-EAU-Congress.aspx)